Nanotechnology-based drug delivery platforms for erectile dysfunction: addressing efficacy, safety, and bioavailability concerns

Erectile dysfunction (ED), is a common and multidimensional sexual disorder, which comprises changes among any of the processes of the erectile response such as organic, relational, and psychological. However, both endocrine and nonendocrine causes of ED produce substantial health implications inclu...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical development and technology 2024-11, Vol.29 (9), p.996-20
Main Authors: Hari Priya, Vijayakumari Mahadevan, Ganapathy A, Anand, Veeran, Midhu George, Raphael M, Shyni, Kumaran, Alaganandam
Format: Article
Language:English
Subjects:
Animals
Biological Availability
Erectile Dysfunction - drug therapy
Humans
Male
Nanomedicine - methods
Nanoparticle Drug Delivery System - chemistry
Nanoparticles
Nanotechnology - methods
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Erectile dysfunction (ED), is a common and multidimensional sexual disorder, which comprises changes among any of the processes of the erectile response such as organic, relational, and psychological. However, both endocrine and nonendocrine causes of ED produce substantial health implications including depression and anxiety due to poor sexual performance, eventually affecting man's life eminence. Marginally invasive interventions following ED consist of lifestyle modifications, oral drugs, injections, vacuum erection devices, etc. Nevertheless, these conventional treatment regimens follow certain drawbacks such as efficacy and safety issues, and navigate to the development of novel therapeutic approaches such as nanomedicine for ED management. Nanotechnology-centred drug delivery platforms are being explored to minimize these limitations with better and effectiveness. Moreover, nanomedicine and nanocarrier-linked approaches are rapidly developing science in the nanoscale range, which contributes to site-specific delivery in a controlled manner and has generated considerable interest prominent to their potential to enhance bioavailability, decrease side effects, and avoidance of first-pass metabolism. This review provides an overview of recent discoveries regarding various nanocarriers and nano-delivery methods, along with current trends in the clinical aspects of ED. Additionally, strategies for clinical translation have been incorporated.
ISSN:1083-7450
1097-9867
1097-9867
DOI:10.1080/10837450.2024.2414379